A novel RyR2-selective stabilizer prevents and ameliorates severe arrhythmias in stress-induced ventricular tachycardia
Nagomi Kurebayashi,Masami Kodama,Takashi Murayama,Masato Konishi,Masami Sugihara,Hana Inoue,Ryosuke Ishida,Koichiro Ishii,Shuichi Mori,Yukari Endo,Xi Zeng,Yukiko U. Inoue,Takayoshi Inoue,Satoru Noguchi,Hajime Nishio,Utako Yokoyama,Junko Kurokawa,Hiroyuki Kagechika,Takashi Sakurai
DOI: https://doi.org/10.1101/2024.11.26.625386
2024-12-02
Abstract:Background: Excessive activation of the type 2 ryanodine receptor (RyR2) causes lethal arrhythmias such as catecholaminergic polymorphic ventricular tachycardia (CPVT). Stabilization of RyR2 in the closed state is expected to prevent the occurrence of these arrhythmias, but there are no clinically available antiarrhythmic drugs that are exclusively RyR2-specific. In this study, we investigated the antiarrhythmic effect of a novel high-affinity and selective RyR2 modulator, Ryanozole, which we have recently developed, using CPVT mouse models harboring mutant RyR2s. Methods: In vitro effects of Ryanozole were assessed by ER Ca -based assay using RyR2-expressing HEK293 cells and [3H]Ryanodine binding assay. To evaluate in situ and in vivo effects of Ryanozole, we used two lines of mice, RyR2-R420W and -K4750Q, with different arrhythmia severity. Intracellular Ca signals were monitored with Cal520 in isolated ventricular cardiomyocytes. Antiarrhythmic effects of drugs (Ryanozole, flecainide, verapamil and atenolol) were evaluated by electrocardiography (ECG) in anesthetized R420W and K4750Q mice challenged with catecholamine and in conscious K4750Q mice that showed activity-dependent arrhythmias. ECG and echocardiographic parameters were analyzed before and after drug administration. Results: Ryanozole suppressed wild type and mutant RyR2s with 15−40 nM IC50, and the inhibition was more potent at low [Ca ] than at high [Ca ] . In isolated cardiomyocytes, Ryanozole suppressed isoproterenol-induced Ca waves and sparks without affecting action potential-evoked Ca transients. Ryanozole effectively suppressed adrenaline-induced arrhythmias and terminated spontaneous arrhythmias during daily activity. Unlike conventional antiarrhythmic drugs, Ryanozole did neither affect ECG parameters nor impair cardiac contractility. Conclusions: This study suggests that selective suppression of RyR2, especially at low [Ca ] , is highly effective in preventing arrhythmias in CPVT without impairing cardiac function. Ryanozole is a promising therapeutic candidate for the prevention and treatment of arrhythmias caused by RyR2 hyperactivation.
Pharmacology and Toxicology